Prolific Machines
Americas
Emeryville
,
United States
Startup
FOUNDED
2020
HEADCOUNT
21-100
FUNDING
Series B
Keywords:
mammalian_cells, AI/ML, bioreactor_design, antibodies, vaccines
BUSINESS
Prolific Machines is developing an optogenetics-based biomanufacturing platform that uses light to control gene expression in production bioreactors. The Photomolecular platform integrates optogenetic cell line engineering, proprietary illumination hardware, and AI-driven bioprocess optimization. Achieved 200-liter optogenetic bioproduction in stainless steel (April 2025). Current focus is mammalian cell applications (antibodies, vaccines, nutritional proteins).
BIOTECH INVOLVEMENT
Core optogenetic biotechnology platform for enhanced bioprocess control.
TECHNOLOGY PLATFORM
optogenetics; AI bioprocess optimization
PRIMARY PRODUCTS
Optogenetic cell lines; illumination systems for bioreactors